Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 15Thyroid Neoplasms 10Thyroid Cancer, Papillary 10Adenocarcinoma, Follicular 9Paraganglioma 4Adrenocortical Carcinoma 4Pheochromocytoma 3Gastro-enteropancreatic neuroendocrine tumor 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Brain Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Testicular Neoplasms 2Somatostatinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Multiple Endocrine Neoplasia Type 1 2Lung Neoplasms 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Adrenal Gland Neoplasms 2Adenoma, Islet Cell 2von Hippel-Lindau Disease 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uveal Melanoma 1Uterine Neoplasms 1

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Digestive System Neuroendocrine Tumor G1 × Magnetic Resonance Spectroscopy × Endocrine × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡